Cognitive function unaffected by combination HRT: study

The six month randomised controlled trial in 23 healthy postmenopausal women, conducted at Monash University, showed that continuous combined estradiol 1mg/drospirenone 2mg (E2D) did not affect overall cognitive performance in the treatment group compared with placebo.

Women in both groups, aged 53 on average, performed similarly on cognitive tests that included visual attention and vigilance, and visual learning and memory, with the only difference being a faster psychomotor function and speed in favour of the placebo group.

Similarly, cognitive tasks measured during functional magnetic resonance imaging,